Recorlev (levoketoconazole)

About Xeris Pharmaceuticals

Xeris Pharmaceuticals is a publicly traded company (NASDAQ: XERS) that has built a commercial portfolio and pipeline around its novel formulation technologies designed to eliminate reconstitution and enable room-temperature stability of injectable drugs. The company's strategy involves both developing its own products and partnering with other biopharma companies to reformulate their injectables. With three FDA-approved products on the market and a pipeline of reformulation candidates, Xeris aims to address significant unmet needs in endocrinology, neurology, and rare diseases.

Therapeutic Areas